Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Abstract: Nineteen patients with K103N present by historical genotype were confirmed by proviral DNA sequencing and 18/19 remained virologically-suppressed.
Transmission dynamics of HIV-1 subtype B in the Basque Country, Spain.
PMID: 26921800
2016
Infection, genetics and evolution
Abstract: The most prevalent mutations for each inhibitor class were PI L90M, NRTI T215D/Y/F, and NNRTI K103N, which were also among the most prevalent resistant variants in the whole dataset.
The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.
Method: M46I, I54V, V82A, M46IN88S, G48VI54V, M46IV82TI84V, and G48VI54VV82A mutations were introduced into the PR coding region, and K103N, Y181C, K103NY181C, K101Q, K101QY181C, K101QH221Y, PMID: 26994843
2016
European journal of medicinal chemistry
Abstract: Among them, compound 15b was identified as the most potent inhibitor with EC50 values of 0.11 muM and 2.18 muM against wt and K103N/Y181C double mutant HIV-1 strain (RES056), respectively.
Increasing HIV-1 Drug Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in Rural KwaZulu-Natal, South Africa.
PMID: 27002368
2016
AIDS research and human retroviruses
Abstract: The nonnucleoside reverse transcriptase inhibitor mutation, K103N, was the most common mutation, occurring in 27 (3.8%) of the participants, while nucleoside reverse transcriptase inhibitor (NRTI) SDRMs were detected in 10 (1.4%) of the participants, of whom eight had only a single NRTI SDRM.
Result: Of these, the most common were K103N, V106M, and G190A occurring in 27 (3.9%), 3 (0.4%), and 2 (0.3%) partici
Discussion: The mutations contributing to most of the resistance in 2011 and 2012 were the NNRTI mutations, specifically K103N has been shown to persist in plasma for as long as 3 years in primary infection.
Increasing HIV-1 pretreatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
Abstract: Antiretroviral-naive adults initiating antiretroviral therapy in Nairobi, Kenya were tested for HIV-1 drug resistance at codons K103N, Y181C, G190A, M184V, and K65R using an oligonucleotide ligation assay.
Introduction: Fifteen of the participants had mutations only to NNRTI (K103N, Y181C, G190A), and three had mutations to NNRTI plus lamivudine (M184V).
Introduction: OLA examined point mutations at K103N, Y181C, G190A, and M184V across all s
Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.
PMID: 27070547
2016
Journal of medicinal chemistry
Result: Moreover, eight active compounds (EC50 < 5 nM against IIIB) were further tested in the MT-2 cell line against the multi-NRTI-resistant A17 viral strain with mutants K103N and Y181C, the two major mutants from the first-generation NNRTI drugs.
HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults.
PMID: 27076106
2016
The Journal of antimicrobial chemotherapy
Abstract: Drug resistance mutations were present in 87/115 samples (75.7%); the most common were M184V/I (52.2%) and K103N (35%).
Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY(R) System.
Abstract: In terms of loci, the detection rate of the alleles was greater than 97% for M41L, K65R, M184V and G190A, 91.2% for K101E/Q/P, 91.2% for T215F/Y, 89.9% for K103N/S and 80.5% for L210W.
Introduction: In this study, we established a multiplex assay for detecting the drug resistance mutations at 8 loci (M41L, K65R, K101E/Q/P, K103N/S, M184V, G190A, L210W and T215F/Y), which are as
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Discussion: Mutations K103N and P225H are preferentially selected by EFV, which is a second generation NNRTI.
Discussion: Our mutation pattern analyses showed that the most frequent SDRM were: K103N (4.0%) and P225H (2.0%) for NNRTIs, T215 revertants (2.4%) and M41L (2.0%) for NRTIs, and M46L/I (1.2%) for PIs.
Discussion: Previously reported NNRTIs mutations for the 2004 to 2005 period in ARV drug-experienced subjects exposed to AZT or d4T + 3TC or ddI + EFV or NFV or IDV reported K103N at a lower frequency (4.9%), together with mutations
ViMRT
HIV mutation literature information.
PMID: 
2016
HIV clinical trials
